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Abstract
Background: Subsidization is a policy to encourage the purchase and use of goods and services and to promote their affordability
for the poor. The Welfare Organization of Iran subsidizes substance use treatment in order to increase coverage and adherence to
treatment.
Objectives: This study aimed to answer the following questions: is the model efficient? Has the policy resulted in increased coverage
and higher adherence to substance use treatment? How could the model be improved?
Methods: We compared two types of substance use treatments of abstinence-based residential program and outpatient methadone
maintenance. Based on their severity of addiction and retention in treatment clients who benefited from subsidization were com-
pared with other clients. Therefore, 109 clients, 78 from methadone maintenance and 31 from residential abstinence-based programs
were interviewed.
Results: Subsidization had an encouraging effect on clients to enter substance use treatment in both treatment programs (P =
0.001). However, we were unable to find evidence that subsidization helped retention in the treatment (P = 0.389), or that concomi-
tant use of illegal substances in clients on methadone maintenance was lower (P = 0.500). Based on economic status of clients (P
= 0.05) their criminal record (P = 0.001), length of use of substances (P = 0.05), and comorbid psychiatric conditions (P = 0.05), it
was evident that assignment to subsidization in methadone maintenance services was significantly more reasonable, while it was
almost random in abstinence-based residential facilities assignment.
Conclusions: The current model of substance use treatment subsidization is not efficient. Addiction severity subscales and socioe-
conomic status of clients could be considered appropriate factors for assignment to the subsidization program.
Keywords: Treatment Subsidization, Substance Use Treatment, Methadone Maintenance Treatment, Abstinence-Based Treatment,
Iran
1. Background
According to the United Nations Office on Drugs and
Crime (UNODC) (1) in 2017, 35 million people suffered from
substance use disorders and required treatment services
worldwide. The 2017 Global Burden of Disease Study esti-
mated that globally there were 585,000 deaths and 42 mil-
lion years of “healthy” life lost as a result of the use of sub-
stances Based on estimates in the United States the total
cost imposed by 20 million substance users on society in
2011 was as high as $193 billion (2). The cost of substance
use worldwide, accordingly, would be more than $330 bil-
lion. Based on a 2001 study, the cost of substance use for 2.5
million regular and 2.7 million casual substance users in
Iran, was at least $11.7 billion, with adjusted cost per capita
of $3900 per annum, equal to 200% of government tax rev-
enue, 230% of non-oil exports, and 47% of oil exports (3).
Substance use treatment and reduction of demand for sub-
stances is a rational strategy to reduce the high costs of
substance use (4). In a systematic review conducted on
cost-benefit analysis of various substance use treatment
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strategies involving detoxification and maintenance ther-
apy, a high economic return by substance use treatment
programs was evidenced (5).
Substance use treatment involves strategies such as
maintenance therapy and detoxification (6) methadone
maintenance is considered a gold standard for the treat-
ment (7). However, only one in seven people receive treat-
ment (1). Considering that only 15% of substance users
undergo treatment, implementing strategies to increase
treatment coverage would be of more importance than
prioritizing cost-benefit treatments (8). Aside from lim-
ited insight in the need for treatment, affordability is a ma-
jor constraint to seeking substance use treatment (9). For
those who seek treatment, however, treatment costs may
necessitate sacrificing basic needs in favor of substance use
treatment (10). Abstaining from treatment not only may
lead to the relapse of substance use and return of men-
tioned costs, but also may result in other negative conse-
quences such as judicial and punitive system costs (11). In
order to reduce the costs of substance use governments
have taken the policy of subsidizing treatment (12-17). Sub-
sidization of methadone maintenance treatment (MMT)
has shown to double treatment retention rate and reduce
the delay between dependence to substances and entry to
treatment (18). However, arguments against the effective-
ness of substance use treatment subsidization remain an
economic and public health concern (19, 20).
In 2017, 7000 MMT clinics and 1200 abstinence-based
residential facilities in Iran provided services to 900,000
and 400,000 clients, respectively (21). For the same year,
the average cost of treatment for maintenance and res-
idential services was Iranian Rials (IRR) (based on 2017
rate: IRR40,000 = US $1) 1,280,000 and IRR 6,380,000
per month, respectively (22), with the difference that
methadone maintenance is an ongoing treatment for up
to several years while abstinence-based residential treat-
ment, theoretically, is a single shot intervention. In 2017,
Iran State Welfare Organization subsidized both types of
maintenance treatment and abstinence-based residential
service by IRR 1,000,000 and IRR 3,000,000, respectively.
2. Objectives
The objective of the current study was to evaluate the
efficiency of subsidization policy by comparing the two
treatment programs.
3. Methods
Study Design: The study was an applied descriptive-
correlational research conducted in Tehran, Iran, during
fall 2017. A convenience sampling was made from outpa-
tient maintenance and abstinence-based residential ser-
vices where both clients received subsidies and full pay-
ment clients received the same treatment.
Study Participants: A total sample of 109 participants
with 78 cases from outpatient maintenance treatment and
31 cases from residential facilities were recruited. Partici-
pation in this study was voluntary and inclusion criterion
was limited to willingness to provide written consent by
participants, where confidentiality of respondents’ infor-
mation was guaranteed by the researchers.
Tools: In order to measure the severity of substance
use, a validated Persian-translation version (23) of addic-
tion severity index (ASI) (24) was used. The Persian ver-
sion of ASI had 114 questions covering six subscales of med-
ical status, legal status, employment/support status, fam-
ily/social relationship, psychiatric status, and substance
use. We used urine test results for substances in clients’
records as an indicator for measurement of treatment ef-
fectiveness.
Statistical Analysis: Considering our non-parametric
data, we applied Kruskal-Wallis and Mann-Whitney-U sta-
tistical tests in addition to chi-square test to examine sta-
tistical significance of our findings.
4. Results
Demographic characteristics of studied subjects in
methadone maintenance clinics and residential facilities
are shown in Table 1. We used Mann-Whitney U test to com-
pare demographic characteristics of clients from the two
types of services (Table 2). All characteristics were signif-
icantly different between clients according to subsidiza-
tion difference in maintenance treatment services. In MMT
services older clients with less education and with less in-
come were benefiting subsidized treatment. Such a pat-
tern, however, was not present in clients from residential
facilities.
In order to measure the effect of subsidization on re-
tention in treatment, we compared the retention in the
maintenance treatment between clients who received sub-
sidies and control group. We also compared urine test
records between the two groups. As seen in Table 3, there
was no difference between the two groups. This effect was
not measured in the participants from residential services
because they were not followed after completion of a one-
month treatment program.
We asked the participants whether they were aware
that they could apply for treatment subsidy and whether
it worked as an incentive for admission for treatment.
A Kendall statistical test showed that for both clients in
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Age, y 44.0 ± 10.9 34.1 ± 8.9
Education (% high school graduate and above) 29.5 54.8
Monthly income in 3 months prior to admission for
treatment (IRR)
12,500,000 ± 8800000 8,120,000 ± 5700000
Abbreviations: MMT, methadone maintenance treatment; RF, abstinence-based residential facilities.
aValues are expressed as mean ± SD.
Table 2. Comparative Demographic Characteristics of Participants (Mann-Whitney U test)
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Abbreviations: MMT, methadone maintenance treatment; RF, abstinence-based residential facilities.
Table 3. Association Between Receiving Subsidies and Retention in Treatment and
Negative Urine Tests in MMT Group (Pearson-Chi-Square)
Variable Value Significance Level
Retention in treatment 75.999 0.389
Negative urine test for illegal substances 1.014 0.500
Abbreviation: MMT, methadone maintenance treatment.
maintenance treatment and in residential service subsi-
dization had a significant effect in engagement in the treat-
ment (Table 4).
Table 4. Association Between Benefiting Subsidies and Engagement in Treatment
(Kendall Test)
Treatment Type Value Significance Level
Methadone maintenance 0.538 0.000
Abstinence-based residential service 0.776 0.000
We further tested subsidization of treatment accord-
ing to addiction severity subscales. As shown in Table 5,
medical status, substance use, and family/social relation-
ship subscales had played no role in subsidization alloca-
tion. However, for clients in methadone maintenance ser-
vices legal status, employment/support status, and psychi-
atric status were subscales that showed significant differ-
ences according to subsidization status of clients. No such
difference was observed in clients from abstinence-based
residential services.
5. Discussion
According to the World Health Organization (25) in
2009, among 147 countries worldwide, less than 50% had
a specific budget for treating substance use disorders. Tax-
based funding, out-of-pocket payments and social health
insurance were among the foremost methods of Sng treat-
ment for alcohol and substance use disorders. Africa was
the only region in which out-of-pocket payments were re-
ported to be the main funding method for alcohol and sub-
stance use disorder treatment services. The opposite end
of the spectrum is compulsory drug detention and reha-
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Table 5. Subsidization of Treatment According to Addiction Severity Subscales (Mann-Whitney U Test)
























































Abbreviations: MMT, methadone maintenance treatment; RF, abstinence-based residential facilities.
bilitation centers which are generally operated by govern-
ments and are commonly seen in East and South Asia (26).
In the United States, substance use disorder treatment is
financed primarily by federal block grants and state and
local general revenues (27). Subsidization of dispensing
fee in community pharmacy-based MMT programs in Aus-
tralia (18) and subsidization of substance use treatment as
a part of anti-viral therapy program in HIV-infected drug
users in Indonesia (17), India (28), and United States (29) are
among various subsidization policies in the field of sub-
stance use treatment.
In Iran, the monthly fee for methadone substitution
therapy in 2017 with an average daily dose of 80 mg was
around IRR 1,280,000, which was equivalent to 14% of a full-
time minimum wage. At the same time-period, abstinence-
based residential programs had a fee around IRR 6,380,000
- 68% of a full-time minimum wage - for a four-week
detoxification service. It is worth mentioning, however,
that both programs charged their clients below the ad-
vertised fees for a marketing purpose. In 2017, the State
Welfare Organization subsidized both types of mainte-
nance treatment and abstinence-based residential service
by IRR 1,000,000 and IRR 3,000,000, respectively. More-
over, the average nominal cost of Iranian households in
2017 was IRR 26,600,000 compared to nominal income of
IRR 30,500,000 (30), indicating an extremely narrow mar-
gin for treatment costs. This situation with no well-defined
insurance coverage in place for substance use treatment,
leads treatment clients and their families to so called catas-
trophic payment (31).
A study in Vietnam (32), recommended government
subsidies for people of lower socioeconomic status en-
tering substance use treatment. According to our study,
only a limited number of methadone maintenance and
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abstinence-based residential facilities were enrolled in
subsidization program with enrollment giving a market
privileged position to those services in terms of attract-
ing clients. We were unable to identify a standard method
for selection of specific service to be enrolled in subsidiza-
tion program. Also, inclusion of clients in the program did
not follow a defined criterion and was exclusively based on
program directors’ personal opinion. However, our analy-
sis (Table 4) showed that enrollment in subsidization pro-
gram had played an encouraging role in seeking substance
use treatment. Nevertheless, considering age, level of edu-
cation, and income prior to admission to treatment as indi-
cators for enrolling a client in subsidization program, our
findings (Table 2) show that, compared to residential facili-
ties, the management of methadone maintenance services
has made a meaningful differentiation between clients se-
lected for enrollment in subsidization program and clients
excluded from the program. Therefore, one may conclude
that enrollment in subsidization program in maintenance
treatment facilities followed a logical criterion based on
age, level of education, and average income during three
months prior to admission to the treatment.
Considering the remarkable role of economic indexes
in treatment entry and retention (18), although residen-
tial services did not measure any indicator of progress and
outcome of their intervention, we decided that follow-up
urine test for substances, available in methadone mainte-
nance services, as an indicator for treatment effectiveness.
Our comparison between methadone maintenance clients
according to their enrollment in subsidization program
status did not show a difference in their follow-up urine
tests (Table 3). In other words, we conclude that, at least in
methadone maintenance services, subsidization of treat-
ment did not result in a better outcome.
In the present study, among the subscales measured by
ASI, family/social relationship of cost payers showed no dif-
ference between clients benefiting subsidization and nor-
mal clients in neither of the two services of methadone
maintenance and abstinence-based residential treatment
(Table 5). Employment/support, legal, and psychiatric sta-
tus, however, were subscales that had played a role for en-
rollment in subsidization program in methadone mainte-
nance services but not in residential services. One could,
therefore, conclude that the management of methadone
maintenance services had been sensitive to those sub-
scales as indicators for enlisting clients for treatment sub-
sidization. It has been shown that subsidization of treat-
ment for people with a lower willingness to pay would be
an optimal strategy (33). The results of current study indi-
cated that psychiatric, medical, and substance use status
of clients were associated with willingness to pay for treat-
ment.
Considering that compared to methadone mainte-
nance treatment, abstinence-based residential treatment
programs are extremely ineffective, with relapse rates
of 30% versus 85%, respectively (34, 35), it seems that,
economic-wise, subsidization of the former program
would be of much higher rationale. Moreover, our study
revealed that the process of selection of clients for sub-
sidization in methadone maintenance services was to
some extent according to identified indicators, where
in abstinence-based residential services it followed no
identified order. Furthermore, while treatment cost in
abstinence-based residential programs is theoretically
a one-time payment and in methadone maintenance
program it is a continuous monthly payment the fraction
of treatment fee that was subsidized, almost 80% of a
single monthly fee, did not elicit any rational basis. In fact,
almost the whole of an ineffective treatment (abstinence-
based residential treatment) was subsidized, while only
one monthly bill of a several years treatment program
(methadone maintenance treatment) was covered.
According to the current study, the total reliance of
the subsidization policy on the management of the two
types of services for selection and enrollment of clients for
subsidization program showed a great failure, at least for
the part of abstinence-based residential services where en-
rollment followed no order and was mere random. We,
however, would recommend that the subsidization policy
should be converted into a more delicate health insurance
policy.
5.1. Limitations
This was the first study to evaluate the effectiveness
of substance use subsidization in Iran and could be a ba-
sis for further economic studies. As subjects in this study
were from services that were already covered by subsidiza-
tion program of the welfare organization, potential selec-
tion biases could have happened in our study. However,
we tried to avoid this bias by including clients not en-
joying subsidization program from same services as con-
trol group. Generalization of the results of this study to
the average client seeking substance use treatment and to
other methadone maintenance treatment and abstinence-
based residential programs should be with caution. The
more limited number of samples from abstinence-based
residential services should add to cautious generalization
of findings of this study. Another limitation of this study
is that as a cross-sectional study it sought association be-
tween addiction severity and effectiveness of subsidiza-
tion. Maybe, studies with acceptable follow-up period are
needed to provide a more comprehensive understanding
of the effectiveness of subsidization of substance use treat-
ment.
Iran J Psychiatry Behav Sci. In Press(In Press):e98718. 5
Uncorrected Proof
Ahmadian Moghaddam S et al.
5.2. Conclusions
Our study reviewed and compared the process of sub-
sidization of substance use treatment in two different
programs of abstinence-based residential treatment and
methadone maintenance treatment. We found that enroll-
ment for subsidized treatment in abstinence-based resi-
dential services did not follow an evidence-based rationale.
While we were unable to measure subsidization effect on
treatment outcome in abstinence-based residential treat-
ment, it had no effect on methadone maintenance treat-
ment.
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